Physician profile
Yudhistira K Persaud
NPI 1124201322
$126,555.20
in general payments reported to CMS, 2019-2025
8 companies · $57K in 2025
The $57K reported for 2025 was more than what 96% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $3,600 · 2021: $9,422 · 2022: $8,232 · 2023: $23K · 2024: $26K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Food and Beverage: $3,823 · Consulting Fee: $3,250 · Travel and Lodging: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,525.00 |
| Food and Beverage | $3,823.43 |
| Consulting Fee | $3,250.00 |
| Travel and Lodging | $1,534.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $126,009.56 | 2019-2025 | Nucala, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $271.11 | 2019-2025 | Tezspire |
| Genzyme Corporation | $106.72 | 2022-2025 | |
| Blueprint Medicines Corporation | $52.17 | 2024 | Ayvakit |
| Abbvie INC. | $48.49 | 2022 | |
| Dynavax Technologies Corporation | $34.23 | 2022 | |
| Amgen INC. | $32.92 | 2024 | Tezspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yudhistira Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.